Table 1.
Immunotherapy associated with macrophages
| Strategies | Target | Agent | Tumour | NCT | Start date |
|---|---|---|---|---|---|
| Inhibiting recruitment of monocytes | CCL2-CCR2 inhibitor | CCR2/5 dual antagonist: GVAX | Pancreatic ductal adenocarcinoma | NCT03767582 | 2019 |
| CSF1/CSF1R inhibitor | CSF-1R inhibitor: pexidartinib | Tenosynovial giant cell tumour | NCT04703322 | 2021 | |
| CSF-1R inhibitor: DCC-3014 | Advanced malignant neoplasm | NCT03069469 | 2017 | ||
| Blocking pro-tumour functions | VEGF/VEGFR inhibitor | VEGFR2 inhibitor: apatinib | Sarcoma | NCT04072042 | 2019 |
| Promoting phagocytosis of TAMs | CD47-SIRPα inhibitor | CD47 inhibitor: AK117 | Acute myeloid leukaemia | NCT04980885 | 2021 |
| CD47 inhibitor: STI-6643 | Solid tumour/relapsed solid neoplasm | NCT04900519 | 2021 | ||
| Reprogramming TAMs into an immunostimulatory phenotype | CD40 agonists | SEA-CD40 | Melanoma/carcinoma/NSCLC | NCT04993677 | 2021 |
| PI3Kγ inhibitor | IPI-549 | Head and neck squamous cell carcinoma | NCT03795610 | 2020 | |
| TLR4/7/8/9 agonists | TLR4 agonist: GSK1795091 | Cancer | NCT02798978 | 2017 | |
| TLR7/8 agonist | Advanced solid tumour | NCT04799054 | 2021 | ||
| TLR9 agonist: CMP-001 | Melanoma | NCT04401995 | 2020 | ||
| Inhibiting immune checkpoint proteins | PD-L1 inhibitor | PD-L1 inhibitor treatment | Advanced solid tumours | NCT04157985 | 2019 |
| CTLA4 inhibitor | BMS-986218 | Advanced carcinoma | NCT04785287 | 2021 |
Data were obtained from http://clinicaltrials.gov.